Clinical Roundup University of Arizona Cancer Center’s “Scientific Cafés” provide novel outreach September 15, 2023Vol.49 No.34
Clinical Roundup OneOncology finalizes 25 oncology and hematology pathways September 15, 2023Vol.49 No.34
Clinical Roundup Six-year outcomes from phase III CheckMate-227 show durable long-term survival with Opdivo + Yervoy in first-line treatment of mNSCLC September 15, 2023Vol.49 No.34
Clinical Roundup Intensity-modulated radiation therapy provides long-term benefits in NSCLC September 15, 2023Vol.49 No.34
Clinical Roundup Rybrevant drug combo demonstrates durable PFS in second-line EGFR-mutated NSCLC in CHRYSALIS-2 cohort September 15, 2023Vol.49 No.34
Clinical Roundup UC Irvine-led study links low-dose radiation to higher cancer risk September 15, 2023Vol.49 No.34
Clinical Roundup Kisqali reduced the risk of cancer recurrence while maintaining QOL in phase III study September 15, 2023Vol.49 No.34
Clinical Roundup Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone September 15, 2023Vol.49 No.34
Clinical Roundup Combination immunotherapy treatment effective before lung cancer surgery, phase II study shows September 15, 2023Vol.49 No.34
